Skip to main content

This translation is provided for general access and has no recorded medical-language review.

Editorial general information — not a clinical-review record

Published: Updated: Publisher: Dr. Murat Toktamışoğlu

What should a potency or biological-activity assay show for an exosome product?

Particle count or CD9/CD63 positivity does not demonstrate an intended biological function. A potency assay should measure a defined mechanism-related activity with suitable controls and across lots; a laboratory response is not a guarantee of clinical benefit in people.

This translation has no recorded clinical or medical-language review.

Direct answer

  • Identity asks what a preparation is; potency asks what function it can perform.
  • The cell model, endpoint, dose-response and acceptance range should be disclosed.
  • One cytokine or gene change cannot represent every skin effect and safety outcome.

Connect potency to purpose

If a product claims wound healing, inflammatory modulation or collagen activity, the assay should be biologically related to that specific claim. Cell proliferation, migration, enzyme activity and signaling changes are different endpoints. When the intended mechanism is unclear, selecting one easy marker may not demonstrate meaningful potency.

Validation details

Positive and negative controls, a vehicle control, dose-response, repeatability, sensitivity, specificity and a lot acceptance range are needed. Function after storage or freeze-thaw also requires testing. One positive research experiment is not a routine lot-release method, and a changed assay needs bridging between old and new results.

Limits of clinical translation

More collagen marker in a cell culture does not establish visible facial change, dose, durability or safety in people. Route, barrier, immunity and a co-procedure may change the outcome. A potency certificate does not replace clinical trials or authorization. Do not turn laboratory findings into product promises when product-specific human evidence is absent.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

  1. Microneedling for Facial Rejuvenation: A Systematic Review

    Foppiani JA et al. · 2025

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  2. Evaluating the Effectiveness and Safety of Radiofrequency for Face and Neck Rejuvenation: A Systematic Review

    Austin GK, Struble SL, Quatela VC · 2022

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  3. Energy-Based Devices for the Treatment of Facial Skin Conditions in Skin of Color

    Sanyal RD, Fabi SG · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  4. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication

    U.S. Food and Drug Administration (FDA) · 2025

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  5. A Systematic Review and Meta-Analysis of Efficacy, Safety, and Satisfaction Rates of Laser Combination Treatments vs Laser Monotherapy in Skin Rejuvenation Resurfacing

    Pour Mohammad A et al. · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  6. Outcomes and Adverse Effects of Ablative vs Nonablative Lasers for Skin Resurfacing: A Systematic Review of 1093 Patients

    Mirza HN, Mirza FN, Khatri KA · 2021

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  7. Medical Lasers

    U.S. Food and Drug Administration (FDA) · 2023

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  8. Functional Assays to Assess the Therapeutic Potential of Extracellular Vesicles

    V. V. T. Nguyen et al. · 2020

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  9. Quality and Safety Considerations for Therapeutic Products Based on Extracellular Vesicles

    PMDA Science Board authors · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review

  10. Minimal Information for Studies of Extracellular Vesicles (MISEV2023)

    International Society for Extracellular Vesicles consensus authors · 2024

    Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.

    Editorial source — not a signed clinical review